Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation
| العنوان: | Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation |
|---|---|
| المؤلفون: | Andrey A. Puretskiy, Richard E. Carson, Shu-fei Lin, Joel Lazewatsky, Yi-Hwa Liu, Paul D. Crane, Albert J. Sinusas, Gary V. Heller, Richard B. Sparks, Ajay Srivastava, L. Veronica Lee, Jacqueline Brunetti |
| المصدر: | Journal of Nuclear Medicine. 55:1445-1451 |
| بيانات النشر: | Society of Nuclear Medicine, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, Fluorine Radioisotopes, Biodistribution, Guanidines, Effective dose (radiation), Heart rate, medicine, Humans, Dosimetry, Tissue Distribution, Radiology, Nuclear Medicine and imaging, Radiometry, Radionuclide Imaging, Cardiac imaging, medicine.diagnostic_test, business.industry, Heart, Fluorobenzenes, Blood pressure, Cardiac nerve, Positron emission tomography, Female, Radiopharmaceuticals, Nuclear medicine, business |
| الوصف: | A novel 18F-labeled ligand for the norepinephrine transporter (N-[3-bromo-4-(3-18F-fluoro-propoxy)-benzyl]-guanidine [LMI1195]) is in clinical development for mapping cardiac nerve terminals in vivo using PET. Human safety, whole-organ biodistribution, and radiation dosimetry of LMI1195 were evaluated in a phase 1 clinical trial. Methods: Twelve healthy subjects at 3 clinical sites were injected intravenously with 150–250 MBq of LMI1195. Dynamic PET images were obtained over the heart for 10 min, followed by sequential whole-body images for approximately 5 h. Blood samples were obtained, and heart rate, electrocardiogram, and blood pressure were monitored before and during imaging. Residence times were determined from multiexponential regression of organ region-of-interest data normalized by administered activity (AA). Radiation dose estimates were calculated using OLINDA/EXM. Myocardial, lung, liver, and blood-pool standardized uptake values were determined at different time intervals. Results: No adverse events due to LMI1195 were seen. Blood radioactivity cleared quickly, whereas myocardial uptake remained stable and uniform throughout the heart over 4 h. Liver and lung activity cleared relatively rapidly, providing favorable target-to-background ratios for cardiac imaging. The urinary bladder demonstrated the largest peak uptake (18.3% AA), followed by the liver (15.5% AA). The mean effective dose was 0.026 ± 0.0012 mSv/MBq. Approximately 1.6% AA was seen in the myocardium initially, remaining above 1.5% AA (decay-corrected) through 4 h after injection. The myocardium-to-liver ratio was approximately unity initially, increasing to more than 2 at 4 h. Conclusion: These preliminary data suggest that LMI1195 is well tolerated and yields a radiation dose comparable to that of other commonly used PET radiopharmaceuticals. The kinetics of myocardial and adjacent organ activity suggest that cardiac imaging should be possible with acceptable patient radiation dose. |
| تدمد: | 2159-662X 0161-5505 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13b70c153d9291cff3ff5bf28d60d21 https://doi.org/10.2967/jnumed.114.140137 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....b13b70c153d9291cff3ff5bf28d60d21 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2159662X 01615505 |
|---|